M-M-R® II
RECONSTITUTION USING DILUENT IN A VIAL

To reconstitute the vaccine, use only the diluent supplied since it is free of preservatives or other antiviral substances which might inactivate the vaccine.

Step 1:
To reconstitute the vaccine, first withdraw the entire contents of the diluent vial into a syringe.





Step 2:
Inject all the diluent in the syringe into the vial of lyophilised vaccine.



Step 3:
Gently agitate vial to mix thoroughly.

Step 4:
Withdraw the entire contents of the vial containing the reconstituted vaccine into a syringe.



Change the needle[2] and inject the total volume of reconstituted vaccine as per the following guidelines. See product specific information.

M-M-R® II is a live vaccine, please review product information and check patient eligibility before prescribing[1]

FOR SUBCUTANEOUS OR INTRAMUSCULAR ADMINISTRATION.

Do not inject intravascularly.

Parenteral drug products should be inspected visually for particulate matter and discolouration prior to administration whenever solution and container permit.

It is recommended the vaccine be used as soon as possible after reconstitution. If storage of reconstituted vaccine is necessary, store in a dark place at 2-8°C and discard if not used within 8 hours.

Storage:

Before reconstitution, store the vial of lyophilised vaccine at 2–8°C.

The diluent may be stored separately at room temperature (20 to 25°C) or in the refrigerator (2 to 8°C). **Do not freeze the diluent.**

CAUTION:

A sterile syringe free of preservatives, antiseptics, and detergents should be used for each injection and/or reconstitution of the vaccine because these substances may inactivate the live virus vaccine.

For additional information, please contact Seqirus Medical information on 1800 642 865.

Refer to the Australian Immunisation Handbook[2] for recommendation on reconstitution guidelines. Consider taking appropriate measures to minimise the risk of needle stick injuries and contamination.

PBS Information: M-M-R® II is listed on the NIP. Refer to the NIP and PBS Schedules.

Before prescribing, please review Product Information available at www.seqirus.com.au/products

References: 1. M-M-R® II Approved Product Information. **2.** The Australian Immunisation Handbook https://immunisationhandbook.health.gov.au/ [accessed August 2020]. Product Information is available from Seqirus (Australia) Pty Ltd. Tower 1, Level 12, Collins Square, 727 Collins Street, Melbourne, VIC 3008. ABN 66 120 398 067. Website: www.seqirus.com.au. Medical Information: 1800 642 865. Date of preparation: August 2020. SEQ/MMR2/0720/0006. 000441.

Seqirus™ A CSL COMPANY